~~<i id='DEF6B02828'><strike id='DEF6B02828'><tt id='DEF6B02828'><pre id='DEF6B02828'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：knowledge 2025-09-30 19:32:21 Page View：59954

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： I was wrong about Geron's blood cancer drug. Now, is it a takeover target?
Next article： Sports medicine is finally prioritizing gender equality

explore

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Leading voice in opioid treatment defends methadone clinic system

MarkParrino:"Idon’tthinkthedominantinterestisjustgivinglotsmoretake-homestopatients.There’smoretotre

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

JOSEPHPREZIOSO/AFPviaGettyImagesLONDON—TheU.K.’scost-effectivenesswatchdogsaidThursdayitisnotyetreco